Skip to main content
SpringerLink
Log in

Chordoma of the Sacrum

  • Chapter
  • First Online:
Tumors of the Sacrum

  • 833 Accesses

Abstract

Chordoma is a relatively rare, slow-growing, primary bone tumor with an overall incidence of approximately one per million population and accounts for 1–4% of all malignant bone lesions [1, 2]. Although rare, it represents the most frequent primary malignant bone tumor affecting the sacrum [3]. It has a slowly aggressive and locally invasive behavior, and it is considered a low-grade malignant neoplasm. In fact, it is poorly sensitive to conventional radiotherapy and chemotherapy. Surgical resection of sacral chordoma remains the standard for local disease control, even if it is associated with significant morbidity and repercussions for patient’s quality of life due to the close relationship with relevant neurovascular structures [4]. An increasing number of novel (radio)surgical and pharmacological strategies are currently being investigated [5–7] and may have a role in addressing microscopic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Healey JH, Lane JM. Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am. 1989;20:417–26.

    CAS  PubMed  Google Scholar 

  2. Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer. 2013;119:2029–37.

    Article  PubMed  Google Scholar 

  3. Fabbri N, Ruggieri P. Chordoma. In: Picci P, et al., editors. Atlas of musculoskeletal tumors and tumor like lesions. Switzerland: Springer; 2014. p. 233–8.

    Chapter  Google Scholar 

  4. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19:367–70.

    Article  PubMed  Google Scholar 

  5. Garofalo F, di Summa PG, Christoforidis D, Pracht M, Laudato P, Cherix S, Bouchaab H, Raffoul W, Demartines N, Matter M. Multidisciplinary approach of lumbo-sacral chordoma: from oncological treatment to reconstructive surgery. J Surg Oncol. 2015;112(5):544–54.

    Article  PubMed  Google Scholar 

  6. Amichetti M, Cianchetti M, Amelio D, Enrici RM, Minniti G. Proton therapy in chordoma of the base of the skull: a systematic review. Neurosurg Rev. 2009;32:403–16.

    Article  PubMed  Google Scholar 

  7. Staab A, Rutz HP, Ares C, et al. Spot-scanning-based proton therapy for extracranial chordoma. Int J Radiat Oncol Biol Phys. 2011;81:e489–96.

    Article  PubMed  Google Scholar 

  8. Luschka H. Die Altersveränderungen der Zwischenwirbelknorpel. Virchows Arch A Pathol Anat Histol. 1856;9:311–27.

    Article  Google Scholar 

  9. Kyriakos M, Totty WG, Lenke LG. Giant vertebral notochordal rest: a lesion distinct from chordoma: discussion of an evolving concept. Am J Surg Pathol. 2003;27:396–406.

    Article  PubMed  Google Scholar 

  10. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69–76.

    Article  PubMed  Google Scholar 

  11. Yakkioui Y, van Overbeeke JJ, Santegoeds R, van Engeland M, Temel Y. Chordoma: the entity. Biochim Biophys Acta. 2014;1846(2):655–69.

    CAS  PubMed  Google Scholar 

  12. O’Rahilly R, Meyer DB. The timing and sequence of events in the development of the human vertebral column during the embryonic period proper. Anat Embryol. 1979;157(2):167–76.

    Article  PubMed  Google Scholar 

  13. Schoenwolf GC, Larsen WJ. Third week: becomming trilaminar and establishing body axis, Larsen’s human embryology. Philadelphia: Elsevier/Churchill Livingstone; 2009.

    Google Scholar 

  14. Bumcrot DA, McMahon AP. Somite differentiation. Curr Biol. 1995;5:612–4.

    Article  CAS  PubMed  Google Scholar 

  15. Bami M, Mavrogenis AF, Angelini A, Milonaki M, Mitsiokapa E, Stamoulis D, Soucacos PN. Bone morphogenetic protein signaling in musculoskeletal cancer. J Cancer Res Clin Oncol. 2016;142(10):2061–72.

    Article  CAS  PubMed  Google Scholar 

  16. Liem Jr KF, Jessell TM, Briscoe J. Regulation of the neural patterning activity of sonic hedgehog by secreted BMP inhibitors expressed by notochord and somites. Development. 2000;127:4855–66.

    CAS  PubMed  Google Scholar 

  17. Stemple DL. Structure and function of the notochord: an essential organ for chordate development. Development. 2005;132:2503–12.

    Article  CAS  PubMed  Google Scholar 

  18. Dietrich S, Schubert FR, Gruss P. Altered Pax gene expression in murine notochord mutants: the notochord is required to initiate and maintain ventral identity in the somite. Mech Dev. 1993;44:189–207.

    Article  CAS  PubMed  Google Scholar 

  19. Pourquie O, Coltey M, Teillet MA, Ordahl C, Le Douarin NM. Control of dorsoventral patterning of somitic derivatives by notochord and floor plate. Proc Natl Acad Sci U S A. 1993;90:5242–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Alvares LE, Lours C, El-Hanfy A, Dietrich S. Microsurgical manipulation of the notochord. Methods Mol Biol. 2008;461:289–303.

    Article  CAS  PubMed  Google Scholar 

  21. Claudio DS. Grafting of somites. Methods Mol Biol. 2008;461:277–87.

    Article  PubMed  Google Scholar 

  22. Resende TP, Ferreira M, Teillet MA, Tavares AT, Andrade RP, Palmeirim I. Sonic hedgehog in temporal control of somite formation. Proc Natl Acad Sci U S A. 2010;107(29):12907–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gilbert SF. Developmental biology. Sunderland: Sinauer Associates; 2010.

    Google Scholar 

  24. Moore KL, Persaud TVN, Torchia MG. The developing human: clinically oriented embryology. Philadelphia: Saunders/Elsevier; 2008.

    Google Scholar 

  25. Bogduk N. Embryology and development, Clinical anatomy of the lumbar spine and sacrum. Edinburgh: Elsevier/Churchill Livingstone; 2005. p. 149–63.

    Google Scholar 

  26. Oka Y, Sato Y, Tsuda H, Hanaoka K, Hirai Y, Takahashi Y. Epimorphin acts extracellularly to promote cell sorting and aggregation during the condensation of vertebral cartilage. Dev Biol. 2006;291(1):25–37.

    Article  CAS  PubMed  Google Scholar 

  27. Rodrigo I, Hill RE, Balling R, Münsterberg A, Imai K. Pax1 and Pax9 activate Bapx1 to induce chondrogenic differentiation in the sclerotome. Development. 2003;130(3):473–82.

    Article  CAS  PubMed  Google Scholar 

  28. Hunter CJ, Matyas JR, Duncan NA. The notochordal cell in the nucleus pulposus: a review in the context of tissue engineering. Tissue Eng. 2003;9(4):667–77.

    Article  CAS  PubMed  Google Scholar 

  29. Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y. Intraosseous benign notochordal cell tumours: overlooked precursors of classic chordomas? Histopathology. 2004;44(6):597–602.

    Article  CAS  PubMed  Google Scholar 

  30. Virchow R. Untersuchungen uber die Entwickelung des Schadelgrundes im gesunden und krankhaften Zustande, und uber den Einfluss derselben auf Schadelform, Gesichtsbildung und Gehirnbau. Berl: G. Rimer; 1857. p. 47.

    Google Scholar 

  31. Ribbert H. Uber die Eccondrosis physaliphora spheno-occipitalis. Zentralbl Allg Pathol Anat. 1894;5:457.

    Google Scholar 

  32. Salisbury JR. The pathology of the human notochord. J Pathol. 1993;171:253–5.

    Article  CAS  PubMed  Google Scholar 

  33. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209:157–65.

    Article  CAS  PubMed  Google Scholar 

  34. Shen J, Li C-D, Yang H-L, et al. Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J Clin Neurosci. 2011;18:96–9.

    Article  CAS  PubMed  Google Scholar 

  35. Choi K-S, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation. Dev Dyn. 2008;237:3953–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yang XR, Ng D, Alcorta DA, et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet. 2009;41:1176–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nibu Y, José-Edwards DS, Di Gregorio A. From notochord formation to hereditary chordoma: the many roles of Brachyury. Biomed Res Int. 2013;2013:826435.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Gulluoglu S, Turksoy O, Kuskucu A, Ture U, Bayrak OF. The molecular aspects of chordoma. Neurosurg Rev. 2016;39(2):185–96.

    Article  PubMed  Google Scholar 

  39. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12:1–11.

    Article  CAS  PubMed  Google Scholar 

  40. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66.

    Article  PubMed  Google Scholar 

  41. Chugh R, Tawbi H, Lucas DR, et al. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12:1344–50.

    Article  PubMed  Google Scholar 

  42. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Savvidou OD, Boscainos PJ, Katonis PG, Sim FH. Chordoma of the spine: clinicopathological features, diagnosis, and treatment. Orthopedics. 2004;27(12):1256–63.

    PubMed  Google Scholar 

  43. Anson KM, Byrne PO, Robertson ID, Gullan RW, Montgomery AC. Radical excision of sacrococcygeal tumours. Br J Surg. 1994;81:460–1.

    Article  CAS  PubMed  Google Scholar 

  44. Smith J, Ludwig RL, Marcove RC. Sacrococcygeal chordoma. A clinic radiological study of 60 patients. Skeletal Radiol. 1987;16:37–44.

    Article  CAS  PubMed  Google Scholar 

  45. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TW. A review of the surgical management of sacral chordoma. Eur J Surg Oncol. 2014;40(11):1412–20.

    Article  CAS  PubMed  Google Scholar 

  46. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom JM. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122–34.

    Article  CAS  PubMed  Google Scholar 

  47. Kaiser TE, Pritchard DJ, Unni KK. Clinicopathologic study of sacrococcygeal chordoma. Cancer. 1984;53:2574–8.

    Article  CAS  PubMed  Google Scholar 

  48. Gray SW, Singhabhandhu B, Smith RA, Skandalakis JE. Sacrococcygeal chordoma: report of a case and review of the literature. Surgery. 1975;78:573–82.

    CAS  PubMed  Google Scholar 

  49. Fourney DR, Gokaslan ZL. Current management of sacral chordoma. Neurosurg Focus. 2003;15:9.

    Article  Google Scholar 

  50. Ozaki T, Hillmann A, Winkelmann W. Surgical treatment of sacrococcygeal chordoma. J Surg Oncol. 1997;64(4):274–9.

    Article  CAS  PubMed  Google Scholar 

  51. Dahan H, Arrive L, Wendum D, et al. Retrorectal developmental cysts in adults: Clinical and radiologic-histopathologic review, differential diagnosis, and treatment. Radiographics. 2001;21:575–84.

    Article  CAS  PubMed  Google Scholar 

  52. Williams LS, Rojiani AM, Quisling RG, et al. Retrorectal cyst-hamartomas and sacral dysplasia: MR appearance. AJNR Am J Neuroradiol. 1998;19:1043–5.

    CAS  PubMed  Google Scholar 

  53. Lim KE, Hsu WC, Wang CR. Tailgut cyst with malignancy: MR imaging findings. AJR Am J Roentgenol. 1998;170:1488–90.

    Article  CAS  PubMed  Google Scholar 

  54. Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71:735–40.

    Article  CAS  PubMed  Google Scholar 

  55. Llauger J, Palmer J, Amores S, et al. Primary tumors of the sacrum: diagnostic imaging. AJR Am J Roentgenol. 2000;174:417–24.

    Article  CAS  PubMed  Google Scholar 

  56. Rossleigh MA, Smith J, Yeh SD. Scintigraphic features of primary sacral tumors. J Nucl Med. 1986;27:627–30.

    CAS  PubMed  Google Scholar 

  57. Crapanzano JP, Ali SZ, Ginsberg MS, Zakowski MF. Chordoma: a cytologic study with histologic and radiologic correlation. Cancer. 2001;93:40–51.

    Article  CAS  PubMed  Google Scholar 

  58. Mitchell A, Scheithauer BW, Unni KK, Forsyth PJ, Wold LE, McGivney DJ. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer. 1993;72:2943–9.

    Article  CAS  PubMed  Google Scholar 

  59. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol. 2008;21:1461–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Paidakakos NA, Rovlias A, Rokas E, Theodoropoulos S, Katafygiotis P. Primary clear cell chondrosarcoma of the spine: a case report of a rare entity and a review of the literature. Case Rep Oncol Med. 2012;2012:693137.

    PubMed  PubMed Central  Google Scholar 

  61. Jeffrey PB, Biava CG, Davis RL. Chondroid chordoma. A hyalinized chordoma without cartilaginous differentiation. Am J Clin Pathol. 1995;103(3):271–9.

    Article  CAS  PubMed  Google Scholar 

  62. Saito A, Hasegawa T, Shimoda T, Toda G, Hirohashi S, Tajima G, et al. Dedifferentiated chordoma: a case report. Jpn J Clin Oncol. 1998;28:766–71.

    Article  CAS  PubMed  Google Scholar 

  63. Kim SC, Cho W, Chang UK, Youn SM. Two cases of dedifferentiated chordoma in the sacrum. Korean J Spine. 2015;12(3):230–4.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Meis JM, Raymond AK, Evans HL, Charles RE, Giraldo AA. “De-differentiated” chordoma: a clinicopathologic and immunohistochemical study of three cases. Am J Surg Pathol. 1987;11:516–25.

    Article  CAS  PubMed  Google Scholar 

  65. Bisceglia M, D’Angelo VA, Guglielmi G, Dor DB, Pasguinelli. De-differentiated chordoma of the thoracic spine with rhabdomyosarcomatous differentiations: report of a case and review of the literature. Ann Diagn Pathol 2007;11:262–273.

    Google Scholar 

  66. Kishikawa H, Tanaka K. Chordoma: report of an autopsy case with fibrosarcoma. Acta Pathol Jpn. 1974;24:299–308.

    CAS  PubMed  Google Scholar 

  67. Morimitsu Y, Aoki T, Yokoyama K, Hashimoto H. Sarcomatoid chordoma: chordoma with a massive spindle cell component. Skeletal Radiol. 2000;29:721–5.

    Article  CAS  PubMed  Google Scholar 

  68. Fukuda T, Aihara T, Ban S, Nakajima T, Machinami R. Sacrococcygeal chordoma with malignant spindle cell component: a report of two autopsy cases with a review of the literature. Acta Pathol Jpn. 1992;42:448–53.

    CAS  PubMed  Google Scholar 

  69. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH. Operative management of sacral chordoma. J Bone Joint Surg Am. 2005;87:2211–6.

    PubMed  Google Scholar 

  70. Ruggieri P, Angelini A, Ussia G, Montalti M, Mercuri M. Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res. 2010;468:2939–47.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Angelini A, Pala E, Calabrò T, Maraldi M, Ruggieri P. Prognostic factors in surgical resection of sacral chordoma. J Surg Oncol. 2015;112(4):344–51.

    Article  PubMed  Google Scholar 

  72. Jawad MU, Scully SP. Surgery significantly improves survival in patients with chordoma. Spine. 2010;35:117–23.

    Article  PubMed  Google Scholar 

  73. Romeo S, Hogendoorn PC. Brachyury and chordoma: the chondroid-chordoid dilemma resolved? J Pathol. 2006;209:143–6.

    Article  CAS  PubMed  Google Scholar 

  74. Park JB, Lee CK, Koh JS, Lee JK, Park EY, Riew KD. Overexpressions of nerve growth factor and its tropomyosin-related kinase A receptor on chordoma cells. Spine. 2007;32(18):1969–73.

    Article  PubMed  Google Scholar 

  75. Hulen CA, Temple T, Fox WP, Sama AA, Green BA, Eismont FJ. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. 2006;88-A:1532–9.

    Google Scholar 

  76. Randall RL, Bruckner J, Lloyd C, Pohlman TH, Conrad EU. Sacral resection and reconstruction for tumors and tumor-like conditions. Orthopaedics. 2005;28:307–13.

    Google Scholar 

  77. Stener B, Gunterberg B. High amputation of the sacrum for extirpation of tumors. Principles and technique. Spine. 1978;3:351–66.

    Article  CAS  PubMed  Google Scholar 

  78. Varga PP, Szövérfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, Chou D, Quraishi NA, Reynolds JJ, Luzzati A, Williams R, Fehlings MG, Germscheid NM, Lazary A, Rhines LD. Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J. 2015;24(5):1092–101.

    Article  PubMed  Google Scholar 

  79. Hsieh PC, Xu R, Sciubba DM, et al. Long-term clinical outcomes following en bloc resections for sacral chordomas and chondrosarcomas: a series of twenty consecutive patients. Spine. 2009;34:2233–9.

    Article  PubMed  Google Scholar 

  80. Atalar H, Selek H, Yildiz Y, et al. Management of sacrococcygeal chordomas. Int Orthop. 2006;30:514–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Devin C, Chong PY, Holt GE, et al. Level-adjusted perioperative risk of sacral amputations. J Surg Oncol. 2006;94:203–11.

    Article  PubMed  Google Scholar 

  82. Samson IR, Springfield DS, Suit HD, Mankin HJ. Operative treatment of sacrococcygeal chordoma. A review of twenty-one cases. J Bone Joint Surg Am. 1993;75:1476–84.

    Article  CAS  PubMed  Google Scholar 

  83. Angelini A, Ruggieri P. A new surgical technique (modified Osaka technique) of sacral resection by posterior-only approach: description and preliminary results. Spine. 2013;38(3):E185–92.

    Article  PubMed  Google Scholar 

  84. Osaka S, Yoshida Y, Ryu J. Longitudinal osteotomy of lateral sacrum for malignant iliac tumor using modified threadwire saw. J Surg Oncol. 2007;95(3):258–60.

    Article  PubMed  Google Scholar 

  85. Gunterberg B, Kewenter J, Petersen I, Stener B. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg. 1976;63(7):546–54.

    Article  CAS  PubMed  Google Scholar 

  86. Gunterberg B, Norlén L, Stener B, Sundin T. Neurourologic evaluation after resection of the sacrum. Invest Urol. 1975;13(3):183–8.

    CAS  PubMed  Google Scholar 

  87. Gunterberg B, Petersen I. Sexual function after major resection of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Fertil Steril. 1976;27:1146–53.

    Article  CAS  PubMed  Google Scholar 

  88. Zoccali C, Skoch J, Patel AS, Walter CM, Maykowski P, Baaj AA. Residual neurological function after sacral root resection during en-bloc sacrectomy: a systematic review. Eur Spine J. 2016;25. [Epub ahead of print].

    Google Scholar 

  89. Angelini A, Drago G, Trovarelli G, Calabrò T, Ruggieri P. Infection after surgical resection for pelvic bone tumors: an analysis of 270 patients from one institution. Clin Orthop Relat Res. 2014;472(1):349–59.

    Article  PubMed  Google Scholar 

  90. Chen KW, Yang HL, Lu J, et al. Risk factors for postoperative wound infections of sacral chordoma after surgical excision. J Spinal Disord Tech. 2011;24:230–4.

    Article  PubMed  Google Scholar 

  91. Pennicooke B, Laufer I, Sahgal A, Varga PP, Gokaslan ZL, Bilsky MH, Yamada YJ. Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine. 2016;41(Suppl 20):S186–92.

    Article  PubMed  Google Scholar 

  92. Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer. 1985;56:182–7.

    Article  CAS  PubMed  Google Scholar 

  93. Catton C, O’Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol. 1996;41:67–72.

    Article  CAS  PubMed  Google Scholar 

  94. Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:633–42.

    Article  CAS  PubMed  Google Scholar 

  95. Rotondo RL, Folkert W, Liebsch NJ, et al. High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. J Neurosurg Spine. 2015;23:788–97.

    Article  PubMed  Google Scholar 

  96. Zabel-du Bois A, Nikoghosyan A, Schwahofer A, et al. Intensity modulated radiotherapy in the management of sacral chordoma in primary versus recurrent disease. Radiother Oncol. 2010;97:408–12.

    Article  PubMed  Google Scholar 

  97. Hug EB, Fitzek MM, Liebsch NJ, et al. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys. 1995;31:467–76.

    Article  CAS  PubMed  Google Scholar 

  98. Yamada Y, Laufer I, Cox BW, et al. Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. Neurosurgery. 2013;73:673–80.

    Article  PubMed  Google Scholar 

  99. Brown JM, Koong AC. High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys. 2008;71:324–5.

    Article  PubMed  Google Scholar 

  100. Suit HD, Goitein M, Munzenrider J, et al. Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine. J Neurosurg. 1982;56:377–85.

    Article  CAS  PubMed  Google Scholar 

  101. Austin-Seymour M, Munzenrider JE, Goitein M, et al. Progress in low-LET heavy particle therapy: intracranial and paracranial tumors and uveal melanomas. Radiat Res Suppl. 1985;8:219–26.

    Article  Google Scholar 

  102. Tobias CA, Blakely EA, Alpen EL, et al. Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys. 1982;8:2109–20.

    Article  CAS  PubMed  Google Scholar 

  103. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110:115–22.

    Article  PubMed  Google Scholar 

  104. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma. Int J Radiat Oncol Biol Phys. 2013;87:1107–14.

    Article  PubMed  Google Scholar 

  105. Indelicato DJ, Rotondo RL, Begosh-Mayne D, et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys. 2016;95:297–303.

    Article  PubMed  Google Scholar 

  106. Scholz M, Kraft G. Track structure and the calculation of biological effects of heavy charged particles. Adv Space Res. 1996;18:5–14.

    Article  CAS  PubMed  Google Scholar 

  107. Imai R, Kamada T, Tsuji H, et al. Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res. 2004;10:5741–6.

    Article  CAS  PubMed  Google Scholar 

  108. Nishida Y, Kamada T, Imai R, et al. Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys. 2011;79:110–6.

    Article  PubMed  Google Scholar 

  109. Imai R, Kamada T, Sugahara S, et al. Carbon ion radiotherapy for sacral chordoma. Br J Radiol. 2011;84(Spec. No. 1):S48–54.

    Google Scholar 

  110. Uhl M, Welzel T, Jensen A, Ellerbrock M, Haberer T, Jäkel O, Herfarth K, Debus J. Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma. Strahlenther Onkol. 2015;191(7):597–603.

    Article  PubMed  Google Scholar 

  111. Lundkvist J, Ekman M, Ericsson SR, Jönsson B, Glimelius B. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol. 2005;44:850–61.

    Article  PubMed  Google Scholar 

  112. Durante M, Loeffler JS. Charged particles in radiation oncology. Nat Rev Clin Oncol. 2010;7:37–43.

    Article  PubMed  Google Scholar 

  113. Mohan R, Bortfeld T. Proton therapy: clinical gains through current and future treatment programs. Front Radiat Ther Oncol. 2011;43:440–64.

    Article  PubMed  Google Scholar 

  114. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol. 2008;26:175–6.

    Article  PubMed  Google Scholar 

  115. Park L, Delaney TF, Liebsch NJ, et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys. 2006;65:1514–21.

    Article  PubMed  Google Scholar 

  116. Suit H, Kooy H, Trofimov A, et al. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No. Radiother Oncol. 2008;86:148–53.

    Article  PubMed  Google Scholar 

  117. Patt JC. CORR Insights(®): sacral insufficiency fractures are common after high-dose radiation for sacral chordomas treated with or without surgery. Clin Orthop Relat Res. 2016;474(3):773–5.

    Article  PubMed  Google Scholar 

  118. Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer. 2007;96:180–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. 2004;101:2086–97.

    Article  CAS  PubMed  Google Scholar 

  120. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20:1886–94.

    Article  CAS  PubMed  Google Scholar 

  121. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Tamborini E, Virdis E, Negri T, et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro-Oncology. 2010;12:776–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30:914–20.

    Article  CAS  PubMed  Google Scholar 

  124. Weinberger PM, Yu Z, Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005;131:707–11.

    Article  PubMed  Google Scholar 

  125. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie. 2006;29:572–4.

    PubMed  Google Scholar 

  126. Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs. 2009;20:953–5.

    Article  CAS  PubMed  Google Scholar 

  127. Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931–6.

    Article  CAS  PubMed  Google Scholar 

  128. Yang C, Schwab JH, Schoenfeld AJ, et al. A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther. 2009;8:2597–605.

    Article  CAS  PubMed  Google Scholar 

  129. Yang C, Hornicek FJ, Wood KB, et al. Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. Spine. 2010;35:1668–75.

    Article  PubMed  Google Scholar 

  130. Thieblemont C, Biron P, Rocher F, Bouhour D, Bobin JY, Gérard JP, et al. Prognostic factors in chordoma: role of postoperative radiotherapy. Eur J Cancer. 1995;31A:2255–9.

    Article  CAS  PubMed  Google Scholar 

  131. McGirt MJ, Gokaslan ZL, Chaichana KL. Preoperative grading scale to predict survival in patients undergoing resection of malignant primary osseous spinal neoplasms. Spine J. 2011;11(3):190–6. doi:10.1016/j.spinee.2011.01.013.

    Article  PubMed  Google Scholar 

  132. Ozger A, Eralp L, Sungur M, Atalar AC. Surgical management of sacral chordoma. Acta Orthop Belg. 2010;76:243–53.

    PubMed  Google Scholar 

  133. Lee J, Bhatia N, Hoang B, Ziogas A, Zell J. Analysis of prognostic factors for patients with chordoma with use of the California Cancer Registry. J Bone Joint Surg Am. 2012;94:356–63.

    Article  PubMed  Google Scholar 

  134. Hobusch GM, Bodner F, Walzer S, Marculescu R, Funovics PT, Sulzbacher I, Windhager R, Panotopoulos J. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum—a single center pilot study. World J Surg Oncol. 2016;14:111.

    Article  PubMed  PubMed Central  Google Scholar 

  135. Hanna SA, Aston WJ, Briggs TW, Cannon SR, Saifuddin A. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res. 2008;466(9):2217–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M, Chevalley F, Gasbarrini A, Picci P, Weinstein JN. Chordoma of the mobile spine: fifty years of experience. Spine. 2006;31(4):493–503.

    Article  PubMed  Google Scholar 

  137. Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, et al. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17:211–9.

    Article  PubMed  Google Scholar 

  138. von Witzleben A, Goerttler LT, Lennerz J, Weissinger S, Kornmann M, Mayer-Steinacker R, von Baer A, Schultheiss M, Möller P, Barth TF. In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients’ shorter overall survival. Eur Spine J. 2016;25:4016–24.

    Article  Google Scholar 

  139. Ridenour 3rd RV, Ahrens WA, Folpe AL, Miller DV. Clinical and histopathologic features of chordomas in children and young adults. Pediatr Dev Pathol. 2010;13(1):9–17.

    Article  PubMed  Google Scholar 

  140. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson Jr RC. Lumbosacral chordoma. Prognostic factors and treatment. Spine. 1999;24:1639–45.

    Article  CAS  PubMed  Google Scholar 

  141. Chen KW, Yang HL, Lu J, Liu JY, Chen XQ. Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord. 2009;48:166–71.

    Article  PubMed  Google Scholar 

  142. Ishii K, Chiba K, Watanabe M, Yabe H, Fujimura Y, Toyama Y. Local recurrence after S2-3 sacrectomy in sacral chordoma. Report of four cases. J Neurosurg. 2002;97(1 Suppl):98–101.

    PubMed  Google Scholar 

  143. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203–10.

    Article  CAS  PubMed  Google Scholar 

  144. Mukherjee D, Chaichana KL, Parker SL, Gokaslan ZL, McGirt MJ. Association of surgical resection and survival in patients with malignant primary osseous spinal neoplasms from the surveillance, epidemiology, and end results (SEER) database. Eur Spine J. 2012;22:1375.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We would like to thank Pierpaolo Furlano for the production of research drawings which formed the basis of the final drawings in this chapter.

Author information

Authors and Affiliations

  1. Department of Orthopaedics and Orthopedic Oncology, University of Padova, Padova, Italy

    Andrea Angelini M.D., Ph.D. & Pietro Ruggieri M.D., Ph.D.

Authors
  1. Andrea Angelini M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pietro Ruggieri M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pietro Ruggieri M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Padova, Italy

    Pietro Ruggieri

  2. Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Padova, Italy

    Andrea Angelini

  3. Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy

    Daniel Vanel

  4. Laboratory of Experimental Oncology, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy

    Piero Picci

Ethics declarations

No benefits have been or will be received from a commercial party related directly or indirectly to the subject matter of this article.

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Angelini, A., Ruggieri, P. (2017). Chordoma of the Sacrum. In: Ruggieri, P., Angelini, A., Vanel, D., Picci, P. (eds) Tumors of the Sacrum. Springer, Cham. https://doi.org/10.1007/978-3-319-51202-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51202-0_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51200-6

  • Online ISBN: 978-3-319-51202-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation